BRPI0815709A2 - composro, composição farmacêutica, e, uso de um composto. - Google Patents

composro, composição farmacêutica, e, uso de um composto.

Info

Publication number
BRPI0815709A2
BRPI0815709A2 BRPI0815709A BRPI0815709A BRPI0815709A2 BR PI0815709 A2 BRPI0815709 A2 BR PI0815709A2 BR PI0815709 A BRPI0815709 A BR PI0815709A BR PI0815709 A BRPI0815709 A BR PI0815709A BR PI0815709 A2 BRPI0815709 A2 BR PI0815709A2
Authority
BR
Brazil
Prior art keywords
composition
compound
pharmaceutical composition
pharmaceutical
Prior art date
Application number
BRPI0815709A
Other languages
English (en)
Inventor
David Jones Clifford
Michael Andrews David
Simpson Iain
Andrew Ward Richard
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0815709A2 publication Critical patent/BRPI0815709A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0815709A 2007-08-23 2008-08-20 composro, composição farmacêutica, e, uso de um composto. BRPI0815709A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95750807P 2007-08-23 2007-08-23
PCT/GB2008/050724 WO2009024824A1 (en) 2007-08-23 2008-08-20 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders

Publications (1)

Publication Number Publication Date
BRPI0815709A2 true BRPI0815709A2 (pt) 2017-06-13

Family

ID=39951669

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0815709A BRPI0815709A2 (pt) 2007-08-23 2008-08-20 composro, composição farmacêutica, e, uso de um composto.

Country Status (19)

Country Link
US (1) US20110118238A1 (pt)
EP (1) EP2212326A1 (pt)
JP (1) JP2010536841A (pt)
KR (1) KR20100057650A (pt)
CN (1) CN103298814A (pt)
AU (1) AU2008290330A1 (pt)
BR (1) BRPI0815709A2 (pt)
CA (1) CA2696200A1 (pt)
CO (1) CO6260060A2 (pt)
CR (1) CR11295A (pt)
DO (1) DOP2010000064A (pt)
EA (1) EA201000341A1 (pt)
EC (1) ECSP10010034A (pt)
MX (1) MX2010002115A (pt)
NI (1) NI201000032A (pt)
NZ (1) NZ584138A (pt)
SV (1) SV2010003491A (pt)
WO (1) WO2009024824A1 (pt)
ZA (1) ZA201001193B (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080119496A1 (en) * 2006-11-16 2008-05-22 Pharmacopeia Drug Discovery, Inc. 7-Substituted Purine Derivatives for Immunosuppression
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
EP2343294A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343297A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343295A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
FR2955109B1 (fr) 2010-01-08 2012-09-07 Sanofi Aventis Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique
UY33452A (es) 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
UY33539A (es) 2010-08-02 2012-02-29 Astrazeneca Ab Compuestos químicos alk
US20140187548A1 (en) * 2010-12-17 2014-07-03 Bayer Intellectual Property Gmbh 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
WO2012080232A1 (en) * 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft 2-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
WO2012080228A1 (en) * 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft 6-thio-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
CA2821829A1 (en) * 2010-12-17 2012-06-21 Bayer Intellectual Property Gmbh Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
US20140135319A1 (en) * 2010-12-17 2014-05-15 Bayer Intellectual Property Gmbh 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
US9284317B2 (en) * 2010-12-17 2016-03-15 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-a]pyrazines as MPS-1 inhibitors
US20140120087A1 (en) 2011-04-21 2014-05-01 Bayer Intellectual Property Gmbh Triazolopyridines
WO2012160029A1 (en) 2011-05-23 2012-11-29 Bayer Intellectual Property Gmbh Substituted triazolopyridines
UA112096C2 (uk) 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
JP6166289B2 (ja) 2012-03-14 2017-07-19 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾピリダジン
CN104603136B (zh) 2012-07-10 2017-06-27 拜耳医药股份有限公司 制备取代的三唑并吡啶的方法
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
CA2914516A1 (en) * 2013-06-07 2014-12-11 Bayer Pharma Aktiengesellschaft Substituted triazolopyridines
CA2914745A1 (en) 2013-06-11 2014-12-18 Bayer Pharma Aktiengesellschaft Prodrug derivatives of substituted triazolopyridines
GB201403536D0 (en) * 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
EP3283642B1 (en) 2015-04-17 2023-10-11 Netherlands Translational Research Center Holding B.V. Prognostic biomarkers for ttk inhibitor chemotherapy
DK3558997T3 (da) 2016-12-20 2021-04-19 Astrazeneca Ab Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer
US11052091B2 (en) 2016-12-21 2021-07-06 Ono Pharmaceutical Co., Ltd. BRK inhibitory compound
TWI820146B (zh) * 2018-06-15 2023-11-01 瑞典商阿斯特捷利康公司 嘌呤酮化合物及其在治療癌症中之用途
BR112021017829A2 (pt) * 2019-03-13 2021-11-30 Voronoi Inc Composto, e, composição farmacêutica para uso em prevenir ou tratar câncer
BR112022020962A2 (pt) * 2020-04-17 2022-12-06 Chengdu Baiyu Pharmaceutical Co Ltd Derivados de imidazolidinona e uso médico dos mesmos
KR102409595B1 (ko) * 2020-06-29 2022-06-17 한국과학기술연구원 단백질 카이네이즈 csf-1r 억제제로서의 신규 퓨리논 유도체
CZ309356B6 (cs) * 2020-09-15 2022-09-28 Ústav experimentální botaniky AV ČR, v. v. i Substituované purinové sloučeniny jako inhibitory proteinkináz, jejich použití jako léčiva a farmaceutické přípravky obsahující tyto deriváty
TW202241901A (zh) * 2020-12-21 2022-11-01 大陸商江蘇恆瑞醫藥股份有限公司 嘌呤酮衍生物、其製備方法及其在醫藥上的應用
CN116917288B (zh) * 2021-03-22 2026-04-14 成都赜灵生物医药科技股份有限公司 一种7,9-二氢嘌呤衍生物及其制药用途
CN117321057A (zh) * 2021-08-23 2023-12-29 成都百裕制药股份有限公司 一种咪唑啉酮衍生物的制备工艺及其中间体
MX2024003693A (es) * 2021-09-23 2024-04-09 Chengdu Baiyu Pharmaceutical Co Ltd Forma cristalina del derivado de imidazolinona.
US20260027122A1 (en) * 2022-07-13 2026-01-29 Chengdu Baiyu Pharmaceutical Co., Ltd. Use of imidazolinone derivative in combination with radiotherapy in treatment of tumors
US20260034136A1 (en) * 2022-07-20 2026-02-05 Kangbaida (Sichuan) Biotechnology Co., Ltd. Use of imidazolinone derivative combined with doxorubicin in treatment of tumors
CN118027034A (zh) * 2022-11-11 2024-05-14 成都百裕制药股份有限公司 嘌呤衍生物及其在医药上的应用
KR20250140519A (ko) * 2022-12-13 2025-09-25 캉바이다 (시추안) 바이오테크놀로지 씨오. 엘티디. 이미다졸리논 화합물의 약학적 제제, 이의 제조방법, 및 이의 용도
CN122206446A (zh) * 2023-09-21 2026-06-12 康百达（四川）生物医药科技有限公司 咪唑啉酮衍生物在制备用于联合放疗治疗肿瘤的药物中的应用及治疗方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5190271B2 (ja) * 2005-01-14 2013-04-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キナーゼ阻害剤としての５員の環付加複素環式ピリミジン
WO2006091737A1 (en) * 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
TWI398252B (zh) * 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途

Also Published As

Publication number Publication date
CA2696200A1 (en) 2009-02-26
ECSP10010034A (es) 2010-04-30
CO6260060A2 (es) 2011-03-22
CN103298814A (zh) 2013-09-11
US20110118238A1 (en) 2011-05-19
AU2008290330A1 (en) 2009-02-26
ZA201001193B (en) 2010-10-27
EP2212326A1 (en) 2010-08-04
CR11295A (es) 2010-05-28
SV2010003491A (es) 2010-07-06
NZ584138A (en) 2011-10-28
EA201000341A1 (ru) 2010-10-29
MX2010002115A (es) 2010-06-01
WO2009024824A1 (en) 2009-02-26
DOP2010000064A (es) 2010-03-31
NI201000032A (es) 2010-12-07
JP2010536841A (ja) 2010-12-02
KR20100057650A (ko) 2010-05-31

Similar Documents

Publication Publication Date Title
BRPI0716171A2 (pt) composto, composiÇço farmacÊutica e uso de um composto.
BRPI0810696A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI1007018A2 (pt) composto, composição farmacêutica, e , uso de um composto.
BRPI0919942A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0907562A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0921375A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI1008906A2 (pt) composto, composição farmacêutica, e, uso de um composto.
BRPI0810161A2 (pt) Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto
BRPI0609802A2 (pt) composto, composição farmacêutica e uso de um composto
BRPI0921879A2 (pt) composto, composição farmacêutica , e, uso de um composto
BRPI0812942A2 (pt) Composto, composição farmacêutica e uso de um composto
BRPI0917579A2 (pt) composto, composição farmacêutica, métodos, e, uso de um composto
BRPI0810019A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI1016219A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI1008793A2 (pt) composto, uso de um composto, e, composição farmacêutica
BRPI0614205A2 (pt) composto, composição farmacêutica, e, uso de composto
BRPI0821115A2 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BRPI0716698A2 (pt) Composto, composição farmacêutica e uso de um composto
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
BRPI1009757A2 (pt) composto, composição farmacêutica, e , uso de um composto.
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
BRPI0618904A2 (pt) composto, composição farmacêutica, e, uso do composto
BRPI0819696A2 (pt) Compostos de derivados de 2-fenil-pirimidina, composição farmacêutica e uso de um composto
BRPI0906937A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0917001A2 (pt) composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]